Mitophagy or how to control the Jekyll and Hyde embedded in mitochondrial metabolism: Implications for melanoma progression and drug resistance

Pigment Cell and Melanoma Research

Volumn 25, Issue 6, 2012, Pages 721-731

  Soengas, María S ^a  

^a Structural Biology and Biocomputing Programme   (Spain)

Author keywords

Drug resistance; Mitochondrial metabolism; Mitophagy

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYTOCHROME C; GLUTAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; MELANIN; MEMBRANE PROTEIN; MITOCHONDRIAL DNA; PARKIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TRICARBOXYLIC ACID; UBIQUITINATED PROTEIN;

APOPTOSIS; ARTICLE; AUTOPHAGOSOME; CANCER GROWTH; CELL FATE; CELL METABOLISM; CELL SURVIVAL; CELL VIABILITY; DNA DAMAGE; DRUG RESISTANCE; HOMEOSTASIS; HUMAN; HYPOXIA; INFLAMMATION; INNATE IMMUNITY; MELANOMA; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL RESPIRATION; MITOPHAGY; NONHUMAN; PARKINSON DISEASE; SOLAR RADIATION; TRANSLATIONAL RESEARCH;

ANIMALS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; MELANOMA; MITOCHONDRIA; MITOCHONDRIAL DEGRADATION; SKIN NEOPLASMS;

EID: 84867918691     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12021     Document Type: Article

References (137)

1. Afanas'ev, I.B. (2010). Signaling by reactive oxygen and nitrogen species in skin diseases. Curr. Drug Metab. 11, 409-414.
2. Alonso-Curbelo, D., and Soengas, M.S. (2009). Self-killing of melanoma cells by cytosolic delivery of dsRNA: wiring innate immunity for a coordinated mobilization of endosomes, autophagosomes and the apoptotic machinery in tumor cells. Autophagy 6, 148-150.
3. Apostolova, N., Blas-Garcia, A., and Esplugues, J.V. (2011). Mitochondria sentencing about cellular life and death: a matter of oxidative stress. Curr. Pharm. Des. 17, 4047-4060.
4. Apte, R.N., Dotan, S., Elkabets, M., White, M.R., Reich, E., Carmi, Y., Song, X., Dvozkin, T., Krelin, Y., and Voronov, E. (2006). The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 25, 387-408.
5. Ashrafi, G., and Schwarz, T.L. (2012). The pathways of mitophagy for quality control and clearance of mitochondria. Cell Death Differ. [E-pub ahead of print] doi: 10.1038/cdd.2012.81.
6. Bailey, C.M., Morrison, J.A., and Kulesa, P.M. (2012). Melanoma revives an embryonic migration program to promote plasticity and invasion. Pigment Cell Melanoma Res. 25, 573-583.
7. Baker, A.F., Landowski, T., Dorr, R., Tate, W.R., Gard, J.M., Tavenner, B.E., Dragovich, T., Coon, A., and Powis, G. (2007). The antitumor agent imexon activates antioxidant gene expression: evidence for an oxidative stress response. Clin. Cancer Res. 13, 3388-3394.
8. Barbieri, C.E., Baca, S.C., Lawrence, M.S. et al. (2012). Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685-689.
9. Barbosa, I.A., Machado, N.G., Skildum, A.J., Scott, P.M., and Oliveira, P.J. (2012). Mitochondrial remodeling in cancer metabolism and survival: potential for new therapies. Biochim. Biophys. Acta 1826, 238-254.
10. Batinic-Haberle, I., Reboucas, J.S., and Spasojevic, I. (2010). Superoxide dismutase mimics: chemistry, pharmacology, and therapeutic potential. Antioxid. Redox Signal. 13, 877-918.
11. Bedogni, B., Welford, S.M., Cassarino, D.S., Nickoloff, B.J., Giaccia, A.J., and Powell, M.B. (2005). The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell 8, 443-454.
12. Bedogni, B., Warneke, J.A., Nickoloff, B.J., Giaccia, A.J., and Powell, M.B. (2008). Notch1 is an effector of Akt and hypoxia in melanoma development. J. Clin. Invest. 118, 3660-3670.
13. Belgnaoui, S.M., Paz, S., and Hiscott, J. (2011). Orchestrating the interferon antiviral response through the mitochondrial antiviral signaling (MAVS) adapter. Curr. Opin. Immunol. 23, 564-572.
14. Berger, M.F., Hodis, E., Heffernan, T.P. et al. (2012). Melanoma genome sequencing reveals frequent PREX2 mutations. Nature, 485, 502-506.
15. Brar, S.S., Kennedy, T.P., Whorton, A.R., Sturrock, A.B., Huecksteadt, T.P., Ghio, A.J., and Hoidal, J.R. (2001). Reactive oxygen species from NAD(P)H:quinone oxidoreductase constitutively activate NF-kappaB in malignant melanoma cells. Am. J. Physiol. Cell Physiol. 280, C659-C676.
16. Chan, N.C., and Chan, D.C. (2011). Parkin uses the UPS to ship off dysfunctional mitochondria. Autophagy 7, 771-772.
17. Chan, N.C., Salazar, A.M., Pham, A.H., Sweredoski, M.J., Kolawa, N.J., Graham, R.L., Hess, S., and Chan, D.C. (2011). Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy. Hum. Mol. Genet. 20, 1726-1737.
18. Checinska, A., and Soengas, M.S. (2012). The gluttonous side of malignant melanoma: basic and clinical implications of macroautophagy. Pigment Cell Melanoma Res. 24, 1116-1132.
19. Cheng, G.C., Schulze, P.C., Lee, R.T., Sylvan, J., Zetter, B.R., and Huang, H. (2004). Oxidative stress and thioredoxin-interacting protein promote intravasation of melanoma cells. Exp. Cell Res. 300, 297-307.
20. Chin, L., Merlino, G., and DePinho, R.A. (1998). Malignant melanoma: modern black plague and genetic black box. Genes Dev. 12, 3467-3481.
21. Cloonan, S.M., and Choi, A.M. (2011). Mitochondria: commanders of innate immunity and disease? Curr. Opin. Immunol. 24, 32-40.
22. Copeland, W.C. (2011). Defects in mitochondrial DNA replication and human disease. Crit. Rev. Biochem. Mol. Biol. 47, 64-74.
23. Dang, C.V. (2012). Links between metabolism and cancer. Genes Dev. 26, 877-890.
24. Deretic, V. (2012). Autophagy: an emerging immunological paradigm. J. Immunol. 189, 15-20.
25. Dewaele, M., Maes, H., and Agostinis, P. (2010). ROS-mediated mechanisms of autophagy stimulation and their relevance in cancer therapy. Autophagy 6, 838-854.
26. Dikic, I., Johansen, T., and Kirkin, V. (2010). Selective autophagy in cancer development and therapy. Cancer Res. 70, 3431-3434.
27. Ding, W.X., Ni, H.M., Li, M., Liao, Y., Chen, X., Stolz, D.B., Dorn Ii, G.W., and Yin, X.M. (2010). Nix is critical to two distinct phases of mitophagy: reactive oxygen species (ROS)-mediated autophagy induction and Parkin-ubiqutin-p62-mediated mitochondria priming. J. Biol. Chem. 285, 27879-27890.
28. D'Souza, G.G., Wagle, M.A., Saxena, V., and Shah, A. (2010). Approaches for targeting mitochondria in cancer therapy. Biochim. Biophys. Acta 1807, 689-696.
29. Dummer, R., and Flaherty, K.T. (2012). Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. Curr. Opin. Oncol. 24, 150-154.
30. Dutton-Regester, K., and Hayward, N.K. (2012). Reviewing the somatic genetics of melanoma: from current to future analytical approaches. Pigment Cell Melanoma Res. 25, 144-154.
31. Egan, D.F., Shackelford, D.B., Mihaylova, M.M. et al. (2011). Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 331, 456-461.
32. Emadi, A., and Gore, S.D. (2010). Arsenic trioxide - An old drug rediscovered. Blood Rev. 24, 191-199.
33. Farmer, P.J., Gidanian, S., Shahandeh, B., Di Bilio, A.J., Tohidian, N., and Meyskens Jr, F.L. (2003). Melanin as a target for melanoma chemotherapy: pro-oxidant effect of oxygen and metals on melanoma viability. Pigment Cell Res. 16, 273-279.
34. Ferraro, D., Corso, S., Fasano, E., Panieri, E., Santangelo, R., Borrello, S., Giordano, S., Pani, G., and Galeotti, T. (2006). Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS). Oncogene 25, 3689-3698.
35. Filipp, F.V., Scott, D.A., Ronai, Z.A., Osterman, A.L., and Smith, J.W. (2012). Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells. Pigment Cell Melanoma Res. 25, 375-383.
36. Flaherty, K.T., Hodi, F.S., and Fisher, D.E. (2012). From genes to drugs: targeted strategies for melanoma. Nat. Rev. Cancer 12, 349-361.
37. Fried, L., and Arbiser, J.L. (2008). The reactive oxygen-driven tumor: relevance to melanoma. Pigment Cell Melanoma Res. 21, 117-122.
38. Fruehauf, J.P., and Trapp, V. (2008). Reactive oxygen species: an Achilles' heel of melanoma? Expert Rev. Anticancer Ther. 8, 1751-1757.
39. Fulda, S., and Kroemer, G. (2011). Mitochondria as therapeutic targets for the treatment of malignant disease. Antioxid. Redox Signal. 15, 2937-2949.
40. Fulda, S., Galluzzi, L., and Kroemer, G. (2010). Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov. 9, 447-464.
41. Galloway, C.A., and Yoon, Y. (2012). Mitochondrial morphology in metabolic diseases. Antioxid. Redox Signal. [Epub ahead of print] doi:10.1089/ars.2012.4779.
42. Galluzzi, L., Morselli, E., Kepp, O., Vitale, I., Rigoni, A., Vacchelli, E., Michaud, M., Zischka, H., Castedo, M., and Kroemer, G. (2009). Mitochondrial gateways to cancer. Mol. Aspects Med. 31, 1-20.
43. Garate, M., Wani, A.A., and Li, G. (2010). The NAD(P)H:Quinone Oxidoreductase 1 induces cell cycle progression and proliferation of melanoma cells. Free Radic. Biol. Med. 48, 1601-1609.
44. Gegg, M.E., Cooper, J.M., Chau, K.Y., Rojo, M., Schapira, A.H., and Taanman, J.W. (2010). Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. Hum. Mol. Genet. 19, 4861-4870.
45. Geisler, S., Holmstrom, K.M., Skujat, D., Fiesel, F.C., Rothfuss, O.C., Kahle, P.J., and Springer, W. (2010). PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat. Cell Biol. 12, 119-131.
46. Gomes, L.C., and Scorrano, L. (2012). Mitochondrial morphology in mitophagy and macroautophagy. Biochim. Biophys. Acta [Epub ahead of print].
47. Gottlieb, R.A., and Carreira, R.S. (2010). Autophagy in health and disease. 5. Mitophagy as a way of life. Am. J. Physiol. Cell Physiol. 299, C203-C210.
48. Govindarajan, B., Sligh, J.E., Vincent, B.J. et al. (2007). Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J. Clin. Invest. 117, 719-729.
49. Green, D.R., and Kroemer, G. (2004). The pathophysiology of mitochondrial cell death. Science 305, 626-629.
50. Green, D.R., Galluzzi, L., and Kroemer, G. (2011). Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science 333, 1109-1112.
51. Greene, A.W., Grenier, K., Aguileta, M.A., Muise, S., Farazifard, R., Haque, M.E., McBride, H.M., Park, D.S., and Fon, E.A. (2012). Mitochondrial processing peptidase regulates PINK1 processing, import and Parkin recruitment. EMBO Rep. 13, 378-385.
52. Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
53. Hodis, E., Watson, I.R., Kryukov, G.V. et al. (2012). A landscape of driver mutations in melanoma. Cell 150, 251-263.
54. Hoek, K.S., and Goding, C.R. (2010). Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res. 23, 746-759.
55. Huang, P., Feng, L., Oldham, E.A., Keating, M.J., and Plunkett, W. (2000). Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407, 390-395.
56. Janku, F., McConkey, D.J., Hong, D.S., and Kurzrock, R. (2011). Autophagy as a target for anticancer therapy. Nat. Rev. Clin. Oncol. 8, 528-539.
57. Jansen, M., Ten Klooster, J.P., Offerhaus, G.J., and Clevers, H. (2009). LKB1 and AMPK family signaling: the intimate link between cell polarity and energy metabolism. Physiol. Rev. 89, 777-798.
58. Jin, S.M., and Youle, R.J. (2012). PINK1- and Parkin-mediated mitophagy at a glance. J. Cell Sci. 125, 795-799.
59. Jin, S.M., Lazarou, M., Wang, C., Kane, L.A., Narendra, D.P., and Youle, R.J. (2010). Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. J. Cell Biol. 191, 933-942.
60. Jones, N. (2010). PINK1 targets dysfunctional mitochondria for autophagyin Parkinson disease. Nat Rev Neurol 6, 181.
61. Kadekaro, A.L., Kavanagh, R.J., Wakamatsu, K., Ito, S., Pipitone, M.A., and Abdel-Malek, Z.A. (2003). Cutaneous photobiology. The melanocyte vs. the sun: who will win the final round? Pigment Cell Res. 16, 434-447.
62. Kane, L.A., and Youle, R.J. (2011). PINK1 and Parkin flag Miro to direct mitochondrial traffic. Cell 147, 721-723.
63. Kang, D.C., Gopalkrishnan, R.V., Wu, Q., Jankowsky, E., Pyle, A.M., and Fisher, P.B. (2002). mda-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc. Natl. Acad. Sci. U.S.A. 99, 637-642.
64. Kang, R., Livesey, K.M., Zeh III, H.J., Lotze, M.T., and Tang, D. (2011). Metabolic regulation by HMGB1-mediated autophagy and mitophagy. Autophagy 7, 1256-1258.
65. Kepp, O., Galluzzi, L., Lipinski, M., Yuan, J., and Kroemer, G. (2011). Cell death assays for drug discovery. Nat. Rev. Drug Discov. 10, 221-237.
66. Kim, K.Y., and Sack, M.N. (2012). Parkin in the regulation of fat uptake and mitochondrial biology: emerging links in the pathophysiology of Parkinson's disease. Curr. Opin. Lipidol. 23, 201-205.
67. Kim, H., Scimia, M.C., Wilkinson, D., Trelles, R.D., Wood, M.R., Bowtell, D., Dillin, A., Mercola, M., and Ronai, Z.A. (2011). Fine-tuning of Drp1/Fis1 availability by AKAP121/Siah2 regulates mitochondrial adaptation to hypoxia. Mol. Cell 44, 532-544.
68. Koppenol, W.H., Bounds, P.L., and Dang, C.V. (2011). Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 11, 325-337.
69. Krauthammer, M., Kong, Y., Ha, B.H. et al. (2012). Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006-1014.
70. Krebs, H.A., and Johnson, W.A. (1937). Metabolism of ketonic acids in animal tissues. Biochem. J. 31, 645-660.
71. Kroemer, G., Marino, G., and Levine, B. (2010). Autophagy and the integrated stress response. Mol. Cell 40, 280-293.
72. Lau, E., and Ronai, Z.A. (2012). ATF2 - at the crossroad of nuclear and cytosolic functions. J. Cell Sci. 125, 2815-2824.
73. Lau, E., Kluger, H., Varsano, T., Lee, K., Scheffler, I., Rimm, D.L., Ideker, T., and Ronai, Z.A. (2012). PKCepsilon promotes oncogenic functions of ATF2 in the nucleus while blocking its apoptotic function at mitochondria. Cell 148, 543-555.
74. Lazarou, M., Jin, S.M., Kane, L.A., and Youle, R.J. (2012). Role of PINK1 binding to the TOM complex and alternate intracellular membranes in recruitment and activation of the E3 ligase Parkin. Dev. Cell 22, 320-333.
75. Lee, J.Y., Nagano, Y., Taylor, J.P., Lim, K.L., and Yao, T.P. (2010). Disease-causing mutations in parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy. J. Cell Biol. 189, 671-679.
76. Leikam, C., Hufnagel, A., Schartl, M., and Meierjohann, S. (2008). Oncogene activation in melanocytes links reactive oxygen to multinucleated phenotype and senescence. Oncogene 27, 7070-7082.
77. Lemasters, J.J. (2005). Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging. Rejuvenation Res. 8, 3-5.
78. Levine, A.J., and Puzio-Kuter, A.M. (2010). The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330, 1340-1344.
79. Lisanti, M.P., Martinez-Outschoorn, U.E., Chiavarina, B. et al. (2010). Understanding the "lethal" drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment. Cancer Biol. Ther. 10, 537-542.
80. Liu, L., Feng, D., Chen, G. et al. (2012a). Mitochondrial outer-membrane protein FUNDC1 mediates hypoxia-induced mitophagy in mammalian cells. Nat. Cell Biol. 14, 177-185.
81. Liu, W., Monahan, K.B., Pfefferle, A.D. et al. (2012b). LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell 21, 751-764.
82. Locasale, J.W., Grassian, A.R., Melman, T. et al. (2011). Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat. Genet. 43, 869-874.
83. Lowe, S.W., Ruley, H.E., Jacks, T., and Housman, D.E. (1993). p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957-967.
84. Lowe, S.W., Bodis, S., McClatchey, A., Remington, L., Ruley, H.E., Fisher, D.E., Housman, D.E., and Jacks, T. (1994). p53 status and the efficacy of cancer therapy in vivo. Science 266, 807-810.
85. Malhi, S.S., and Murthy, R.S. (2012). Delivery to mitochondria: a narrower approach for broader therapeutics. Expert Opin. Drug Deliv., 9, 909-935.
86. Mathew, R., and White, E. (2011). Autophagy in tumorigenesis and energy metabolism: friend by day, foe by night. Curr. Opin. Genet. Dev. 21, 113-119.
87. Meyskens Jr, F.L., Farmer, P., and Fruehauf, J.P. (2001). Redox regulation in human melanocytes and melanoma. Pigment Cell Res. 14, 148-154.
88. Meyskens Jr, F.L., Farmer, P.J., Yang, S., and Anton-Culver, H. (2007). New perspectives on melanoma pathogenesis and chemoprevention. Recent Results Cancer Res. 174, 191-195.
89. Mitra, K., Wunder, C., Roysam, B., Lin, G., and Lippincott-Schwartz, J. (2009). A hyperfused mitochondrial state achieved at G1-S regulates cyclin E buildup and entry into S phase. Proc. Natl. Acad. Sci. U.S.A. 106, 11960-11965.
90. Mortensen, M., Ferguson, D.J., and Simon, A.K. (2010). Mitochondrial clearance by autophagy in developing erythrocytes: clearly important, but just how much so? Cell Cycle 9, 1901-1906.
91. Nakayama, K., Qi, J., and Ronai, Z. (2009). The ubiquitin ligase Siah2 and the hypoxia response. Mol. Cancer Res. 7, 443-451.
92. Namiki, T., Tanemura, A., Valencia, J.C. et al. (2011). AMP kinase-related kinase NUAK2 affects tumor growth, migration, and clinical outcome of human melanoma. Proc. Natl. Acad. Sci. U.S.A. 108, 6597-6602.
93. Narendra, D., Kane, L.A., Hauser, D.N., Fearnley, I.M., and Youle, R.J. (2010). p62/SQSTM1 is required for Parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both. Autophagy 6, 1090-1106.
94. Nunnari, J., and Suomalainen, A. (2012). Mitochondria: in sickness and in health. Cell 148, 1145-1159.
95. Okamoto, M., Liu, W., Luo, Y., Tanaka, A., Cai, X., Norris, D.A., Dinarello, C.A., and Fujita, M. (2010). Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J. Biol. Chem. 285, 6477-6488.
96. Peinado, H., Aleckovic, M., Lavotshkin, S. et al. (2012). Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med., 18, 883-891.
97. Pinnix, C.C., and Herlyn, M. (2007). The many faces of Notch signaling in skin-derived cells. Pigment Cell Res. 20, 458-465.
98. Pleasance, E.D., Cheetham, R.K., Stephens, P.J. et al. (2010). A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463, 191-196.
99. Poole, A.C., Thomas, R.E., Yu, S., Vincow, E.S., and Pallanck, L. (2010). The mitochondrial fusion-promoting factor mitofusin is a substrate of the PINK1/parkin pathway. PLoS ONE 5, e10054.
100. Poulikakos, P.I., and Rosen, N. (2011). Mutant BRAF melanomas-dependence and resistance. Cancer Cell 19, 11-15.
101. Qi, J., Nakayama, K., Gaitonde, S., Goydos, J.S., Krajewski, S., Eroshkin, A., Bar-Sagi, D., Bowtell, D., and Ronai, Z. (2008). The ubiquitin ligase Siah2 regulates tumorigenesis and metastasis by HIF-dependent and -independent pathways. Proc. Natl. Acad. Sci. U.S.A. 105, 16713-16718.
102. Rathinam, V.A., Vanaja, S.K., and Fitzgerald, K.A. (2012). Regulation of inflammasome signaling. Nat Immunol. 13, 333-342.
103. Richmond, A., Yang, J., and Su, Y. (2009). The good and the bad of chemokines/chemokine receptors in melanoma. Pigment Cell Melanoma Res. 22, 175-186.
104. Riley, P.A. (1985). Radicals and melanomas. Philos. Trans. R. Soc. Lond. B Biol. Sci. 311, 679-689.
105. Riley, P.A. (2003). Melanogenesis and melanoma. Pigment Cell Res. 16, 548-552.
106. Roesch, A., Fukunaga-Kalabis, M., Schmidt, E.C., Zabierowski, S.E., Brafford, P.A., Vultur, A., Basu, D., Gimotty, P., Vogt, T., and Herlyn, M. (2010). A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141, 583-594.
107. Salaun, B., Lebecque, S., Matikainen, S., Rimoldi, D., and Romero, P. (2007). Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin. Cancer Res. 13, 4565-4574.
108. Scherz-Shouval, R., and Elazar, Z. (2010). Regulation of autophagy by ROS: physiology and pathology. Trends Biochem. Sci. 36, 30-38.
109. Scott, D.A., Richardson, A.D., Filipp, F.V., Knutzen, C.A., Chiang, G.G., Ronai, Z.A., Osterman, A.L., and Smith, J.W. (2011). Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. J. Biol. Chem. 286, 42626-42634.
110. Semenza, G.L. (2009). HIF-1: upstream and downstream of cancer metabolism. Curr. Opin. Genet. Dev. 20, 51-56.
111. Straussman, R., Morikawa, T., Shee, K. et al. (2012). Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504.
112. Strowig, T., Henao-Mejia, J., Elinav, E., and Flavell, R. (2012). Inflammasomes in health and disease. Nature 481, 278-286.
113. Tormo, D., Alonso-Curbelo, D., and Soengas, M.S. (2009a). Cytosolic delivery of dsRNA triggers MDA-5 mediated autonomous cell death in malignant melanomas. Clin. Transl. Oncol. 11, 39-42.
114. Tormo, D., Checinska, A., Alonso-Curbelo, D. et al. (2009b). Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. Cancer Cell 16, 103-114.
115. Trachootham, D., Zhou, Y., Zhang, H. et al. (2006). Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10, 241-252.
116. Tsao, H., Chin, L., Garraway, L.A., and Fisher, D.E. (2012). Melanoma: from mutations to medicine. Genes Dev. 26, 1131-1155.
117. Ueda, Y., and Richmond, A. (2006). NF-kappaB activation in melanoma. Pigment Cell Res. 19, 112-124.
118. Valentin-Vega, Y.A., Maclean, K.H., Tait-Mulder, J., Milasta, S., Steeves, M., Dorsey, F.C., Cleveland, J.L., Green, D.R., and Kastan, M.B. (2011). Mitochondrial dysfunction in ataxia-telangiectasia. Blood 119, 1490-1500.
119. Van Humbeeck, C., Cornelissen, T., and Vandenberghe, W. (2011). Ambra1: a Parkin-binding protein involved in mitophagy. Autophagy 7, 1555-1556.
120. Verhaegen, M., Bauer, J.A., Martin de la Vega, C. et al. (2006). A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res. 66, 11348-11359.
121. Verma, D., Bivik, C., Farahani, E., Synnerstad, I., Fredrikson, M., Enerback, C., Rosdahl, I., and Soderkvist, P. (2012). Inflammasome polymorphisms confer susceptibility to sporadic malignant melanoma. Pigment Cell Melanoma Res. 25, 506-513.
122. Villanueva, J., and Herlyn, M. (2008). Melanoma and the tumor microenvironment. Curr. Oncol. Rep. 10, 439-446.
123. Wang, K., and Klionsky, D.J. (2011). Mitochondria removal by autophagy. Autophagy 7, 297-300.
124. Wang, X., Winter, D., Ashrafi, G., Schlehe, J., Wong, Y.L., Selkoe, D., Rice, S., Steen, J., LaVoie, M.J., and Schwarz, T.L. (2011). PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell 147, 893-906.
125. Wei, X., Walia, V., Lin, J.C. et al. (2012). Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat. Genet. 43, 442-446.
126. Weidberg, H., Shvets, E., and Elazar, Z. (2011). Biogenesis and cargo selectivity of autophagosomes. Annu. Rev. Biochem. 80, 125-156.
127. Weissig, V. (2011). From serendipity to mitochondria-targeted nanocarriers. Pharm. Res. 28, 2657-2668.
128. Westermann, B. (2010). Mitochondrial fusion and fission in cell life and death. Nat. Rev. Mol. Cell Biol. 11, 872-884.
129. Witkiewicz, A.K., Kline, J., Queenan, M., Brody, J.R., Tsirigos, A., Bilal, E., Pavlides, S., Ertel, A., Sotgia, F., and Lisanti, M.P. (2011). Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers. Cell Cycle 10, 1794-1809.
130. Wittgen, H.G., and van Kempen, L.C. (2007). Reactive oxygen species in melanoma and its therapeutic implications. Melanoma Res. 17, 400-409.
131. Yang, Z., and Klionsky, D.J. (2010). Eaten alive: a history of macroautophagy. Nat. Cell Biol. 12, 814-822.
132. Yoshii, S.R., Kishi, C., Ishihara, N., and Mizushima, N. (2011). Parkin mediates proteasome-dependent protein degradation and rupture of the outer mitochondrial membrane. J. Biol. Chem. 286, 19630-19640.
133. Youle, R.J., and Narendra, D.P. (2010). Mechanisms of mitophagy. Nat. Rev. Mol. Cell Biol. 12, 9-14.
134. Zanchetta, L.M., Garcia, A., Lyng, F., Walsh, J., and Murphy, J.E. (2012). Mitophagy and mitochondrial morphology in human melanoma-derived cells post exposure to simulated sunlight. Int. J. Radiat. Biol. 87, 506-517.
135. Zhang, J., and Ney, P.A. (2009). Role of BNIP3 and NIX in cell death, autophagy, and mitophagy. Cell Death Differ. 16, 939-946.
136. Zheng, B., Jeong, J.H., Asara, J.M., Yuan, Y.Y., Granter, S.R., Chin, L., and Cantley, L.C. (2009). Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol. Cell 33, 237-247.
137. Zorov, D.B., Juhaszova, M., and Sollott, S.J. (2006). Mitochondrial ROS-induced ROS release: an update and review. Biochim. Biophys. Acta 1757, 509-517.